Are Janus Kinase Inhibitors Superior Over Classic Biologic Agents in RA Patients?

BioMed Research International - United States
doi 10.1155/2018/7492904
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Hindawi Limited

Related search

Janus Kinase Inhibitors for Autoimmune Disorders

Prescriber
Pharmacology
2017English

SAT0177 Real-World Interruptions in Janus Kinase Inhibitor Therapy Observed Among Biologic-naÏve and Biologic-Experienced Rheumatoid Arthritis Patients

2018English

Development of Selective Covalent Janus Kinase 3 Inhibitors

Journal of Medicinal Chemistry
Drug DiscoveryMolecular Medicine
2015English

Role of Janus Kinase Inhibitors in the Treatment of Alopecia Areata

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2018English

Persistence Rate With Subcutaneous Biologic Therapies in Patients With Rheumatoid Arthritis (Ra)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Janus Kinase Inhibitors and Allogeneic Stem Cell Transplantation for Myelofibrosis

Biology of Blood and Marrow Transplantation
TransplantationHematology
2014English

Janus Kinase V617F Mutation Detection in Patients With Myelofibrosis

Balkan Journal of Medical Genetics
Genetics
2019English

Therapeutic Potential of Janus-Activated Kinase-2 Inhibitors for the Management of Myelofibrosis

Clinical Cancer Research
Cancer ResearchOncology
2010English

Biologic Monotherapy in the Biologic Naïve Patient With Rheumatoid Arthritis (RA): Results From an Observational Study

Rheumatology International
RheumatologyAllergyImmunology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy